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Purpose: The probability of detecting radiologically evident metastatic disease in asymptomatic women with newly
diagnosed operable breast cancer is low. Despite the recommendations of most practice guidelines imaging is still
frequently performed. Relatively little is known about what patients believe is important when it comes to
radiologic staging.
Methods: Patients with early stage breast cancer who had completed their definitive breast surgery were surveyed
about their personal experiences, perceptions, and expectations on the issue of perioperative imaging for distant
metastatic disease.
Results: Over a 3 month period, 245 women with primary operable breast cancer completed the questionnaire
(87.0% response rate) and 80.8% indicated having had at least one imaging test for distant metastatic disease.
These were either of the thorax (72.2%), abdomen (55.9%) or skeleton (65.3%) with a total of 701 imaging tests
(average of 3.5 tests per patient imaged) performed. Overall, 57.1% indicated that they would want imaging done if
the chance of detecting metastases was ≤10%. Although 80.0% of patients indicated that, “doing whatever their
doctor recommended” was important to them, 70.4% also noted that they would be uncomfortable if their
physician did not order imaging, even if this was in keeping with practice guidelines.
Conclusions: Most patients with early stage breast cancer recall having imaging tests for distant metastases. Given
the choice, most would prefer having imaging performed, even if this is not in line with current guidelines. If
patient expectations are, in part, driving excessive imaging, new strategies addressing this are required.
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Patients with asymptomatic, newly diagnosed early stage
breast cancer frequently undergo imaging for distant
metastases (Simos et al. 2013; Barrett et al. 2009;
Al-Husaini et al. 2008; McWhirter et al. 2007; Puglisi et al.
2005; Gerber et al. 2003; Dillman and Chico 2000; Samant
and Ganguly 1999; Ravaioli et al. 1998). Many groups have
shown that the probability of detecting such metastases is
low (Barrett et al. 2009; Puglisi et al. 2005; Gerber et al.* Correspondence: dsimos@toh.on.ca
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in any medium, provided the original work is p2003; Dillman and Chico 2000; Samant and Ganguly
1999; Ravaioli et al. 1998; Al-Husaini et al. 2008; Simos
et al. 2013) with a recent meta-analysis reporting the me-
dian prevalence of metastases as 0.2%, 1.2% and 8% in pa-
tients with stage 1, 2 and 3 disease respectively (Brennan
and Houssami 2012). As this prevalence is significantly
lower than the reported false positive rate of contempor-
ary imaging (Brennan and Houssami 2012; Simos et al.
2013), local (Laing 2012; Myers et al. 2001; Alberta Health
Services clinical practice guideline BR-012 version 2
effective July 2012), national (National Comprehensive
Network (NCCN) clinical practice guidelines in oncology –
Breast Cancer version 1 2014), and international (Senkus
et al. 2013) practice guidelines all generally recommendn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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highlighted (as part of the American Board of Internal
Medicine’s “Choosing Wisely Campaign”) by the American
Society of Clinical Oncology (ASCO) in their inaugural
“Top-5” list for oncology in which the use of staging
imaging in asymptomatic patients with early breast cancer
was discouraged (Schnipper et al. 2012). This recommen-
dation is in keeping with the spirit of the published
guideline recommendations (Myers et al. 2001; Alberta
Health Services clinical practice guideline BR-012
version 2 effective July 2012; Laing 2012; National
Comprehensive Cancer Network (NCCN) clinical practice
guidelines in oncology – Breast Cancer version 1 2014;
Senkus et al. 2013).
While guidelines tend to focus on the role of physi-
cians in ordering appropriate investigations (McWhirter
et al. 2007), little is known about what patients believe is
important when it comes to radiologic staging. We
undertook this study to identify patient experiences with
as well as their perceptions and expectations on this
matter, and to assess whether or not their views are con-
cordant with existing guidelines.
Methods
Questionnaire design and target population
A brief questionnaire consisting of eleven questions
(Additional file 1) was developed by the study team of
medical (DS, MC), radiation (JMC) and surgical (AA)
oncologists as well as experts in epidemiology (BH, IG)
and knowledge translation (IG). Participants were asked
to answer questions about their cancer characteristics,
imaging performed around the time of surgery, and their
opinion and perceptions around the use of imaging tests.
No patient identifiers were used in the data collection
process—all the information gathered was based on pa-
tient recall.
Our target population included all patients who had
completed their definitive breast cancer surgery and
were either on adjuvant treatment or on post-treatment
follow-up. Patients with metastatic disease and/or who
received neoadjuvant chemotherapy and/or who had a
previous history of other malignancies were excluded.
All participants were patients seen at the Ottawa Hos-
pital Cancer Center (TOHCC) which is a large Canadian
academic multidisciplinary cancer centre that routinely
sees approximately 1000 new breast cancer patients a
year.
Questionnaire distribution
Paper copies of the questionnaire with an attached letter
of introduction explaining rationale and aims of the
study were circulated to physicians from the breast can-
cer disease site group who agreed to enroll patients to
this study. Eligible participants were identified theirphysician during one of their regularly scheduled visits
and asked if they would be willing to complete the ques-
tionnaire at the conclusion of this visit. This study was
approved by the Ottawa Hospital Research Ethics Board.
Data analysis
All answers were entered into a Microsoft Excel® work-
sheet for data analysis. The proportion for questions
encompassing categorical responses, as well as median
values and ranges for continuous measures were calcu-
lated. For the number of imaging tests per patient, we
used imaging done to look at the most common sites of
breast metastases: the skeleton (isotope bone scan, plain
x-rays, magnetic resonance imaging (MRI) axial skel-
eton), thorax (x-ray, computerized tomography (CT))
and liver (ultrasound, CT abdomen/pelvis, magnetic res-
onance imaging (MRI)). Tables and bar plots were used
to summarize the pertinent findings.
Results
Patient characteristics
Between March 1 and May 31, 2013, 285 copies of the
questionnaire were distributed. A total of 248 completed
questionnaires were returned (87.0%). Three question-
naires were excluded from the final analysis (N = 245) as
the respondents indicated that they had not yet had their
definitive breast cancer surgery (all 3 indicated they were
on neoadjuvant chemotherapy at the time). Self-reported
patient and disease characteristics of the 245 respon-
dents that were included in the final analysis are shown
in Table 1. Median patient age was 59 years (range 27-88)
and time from breast surgery to completing the question-
naire was < 6 months in 93 (38.0%), 6-12 months in 50
(20.4%), and > 12 months in 94 (38.4%). Disease stage was
reported by 197/245 (80.4%) respondents: 88 (44.7%) were
stage 1, 69 (35.0%) stage 2, and 40 (20.3%) stage 3.
Overall, 198 (80.8%) respondents reported having at
least one imaging test for metastatic disease (Table 2).
The total number of imaging tests recalled by all respon-
dents was 701 for a median of 3 (range 0-11) and an
average of 3.5 imaging tests per patient imaged. Of the
701 total imaging tests performed, 300 (42.8%) were of
the thorax, 213 (30.4%) were of the abdomen, and 188
(26.8%) were of the skeleton. Overall, 476 of all imaging
tests (67.9%) were performed pre-operatively and 225
(32.1%) post-operatively.
Imaging of the thorax was reported by 177 patients
(72.2% overall; 52 stage 1 (59.1%), 55 stage 2 (79.7%), 32
stage 3 (80.0%), and 38 of unknown stage (79.2%)). The
most common imaging modalities for the thorax were
chest x-ray (80 patients), CT scan (19 patients) or both
(78 patients). Imaging of the abdomen was reported by
137 patients (55.9% overall; 38 stage 1 (43.2%), 44 stage
2 (63.8%), 29 stage 3 (72.5%), 26 of unknown stage
Table 1 Patient reported baseline variables
Respondents 245
Median age (range) 59 (27-88)
Method of cancer detection Symptomatic 161 (65.7%)
Screen 81 (33.1%)
Not answered 3 (1.2%)
Time from surgery to
completion of questionnaire
<6 months 93 (38.0%)
6-12 months 50 (20.4%)
>12 months 94 (38.4%)
Not answered 8 (3.3%)








Don’t know 52 (21.2%)
Not answered 8 (3.3%)
Human epidermal growth




Don’t know 87 (35.5%)
Not answered 15 (6.1%)
Triple negative breast cancer Yes 15 (6.1%)
No 114 (46.5%)
Don’t know 85 (34.7%)
Not answered 31 (12.7%)
Lymph node positive breast cancer Yes 103 (42.0%)
No 124 (50.6%)
Don’t know 9 (3.7%)
Not answered 9 (3.7%)
Legend: <: less than; >: greater than.
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abdomen were ultrasound (74 patients), CT scan (16 pa-
tients), MRI (3 patients), or a combination of these (44
patients). Imaging of the skeleton was reported by 160
patients (65.3% overall; 45 stage 1 (51.1%), 49 stage 2
(71.0%), 35 stage 3 (87.5%), 31 of unknown stage
(64.6%)) patients. All respondents reported having an
isotope bone scan.
Acceptable thresholds to perform imaging as reported by
patients
Participants were given a range of probabilities of detect-
ing metastatic disease using imaging and asked to provide
a response (“yes”, “no”, or “don’t know”) for the range they
felt imaging would be acceptable and expected. The prob-
abilities listed were as follows: <1%, 1-5%, 6-10%, 11-20%,
21-30%, 31-50% and >50%. While 69/245 (28.2%) ofpatients indicated that they would want imaging even if
the chance of metastatic disease was <1%, the majority
(140/245; 57.1%) indicated that a probability of detecting
distant metastatic disease of between 6-10% (Figure 1).
Patient reported factors of importance relating to staging
imaging
Patients were asked to indicate how important seven dif-
ferent statements related to staging imaging are to them
using a predefined scale consisting of the following
choices: extremely important, very important, somewhat
important, or not important (Figure 2). Of these 7 state-
ments, 4 were felt by the majority of patients to be either
extremely important or very important to them. These
were: “catching the spread of cancer to other parts of
the body early” (219/245; 89.4%), “reducing the chances
of dying from breast cancer” (211/245; 86.1%), “I would
do whatever my doctor recommends” (196/245; 80.0%),
and “scans will provide peace of mind” (182/245; 74.3%).
The remaining 3 statements were deemed somewhat im-
portant or not important by the majority of respondents.
Patient reported level of comfort if imaging based on
local guidelines
Participants were asked to indicate how comfortable
they would be if their physician, in concordance with the
local Cancer Care Ontario guideline (Myers et al. 2001),
did not perform imaging for metastatic disease (Figure 3).
Overall, 168/245 (68.6%) of respondents indicated they
would feel, “uncomfortable” with this recommendation.
Of the 196 (80.0%) who indicated that doing whatever
their physician recommends is either extremely or very
important to them, 138/196 (70.4%) indicated that they
would be uncomfortable if their physician did not order
imaging to look for metastatic disease.
Discussion
The challenges around controlling excessive staging im-
aging for metastatic disease in asymptomatic early stage
breast cancer are well recognised (McWhirter et al.
2007; Puglisi et al. 2005; Gerber et al. 2003; Dillman and
Chico 2000; Simos et al. 2013; Schnipper et al. 2012)
and despite guidelines recommending against routine
imaging is still frequently over utilised (Barrett et al.
2009; McWhirter et al. 2007; Puglisi et al. 2005; Gerber
et al. 2003; Dillman and Chico 2000; Samant and
Ganguly 1999; Ravaioli et al. 1998; Al-Husaini et al.
2008; Simos et al. 2013). While most reports focus on
diagnostic accuracy of the imaging test (the balance be-
tween true and false positive detection rates), (Barrett
et al. 2009; Puglisi et al. 2005; Simos et al. 2013; Brennan
and Houssami 2012), relatively few have attempted to
evaluate the performance of an imaging test on patient
outcomes including the potential for harm both to the
Table 2 Details of patient reported imaging
A: Summary of patient reported perioperative imaging for distant metastases
Patients reporting at least one imaging test for metastatic disease (%) 198 (80.8%)








Total imaging tests (# per patient imaged) 701 (3.5)
B: Imaging details
Stage 1 (n = 88) Stage 2 (n = 69) Stage 3 (n = 40) Unknown Stage (n = 48)
Thoracic imaging:
Reported in (%) 52 (59.1%) 55 (79.7%) 32 (80.0%) 38 (79.2%)
Total # of imaging tests of chest (% of total of 300) 82 (27.3%) 91 (30.3%) 59 (19.7%) 68 (22.7%)
Imaging details:
CXR only (%) 25 (28.4%) 29 (42.0%) 11 (27.5%) 15 (31.3%)
CT-chest only (%) 9 (10.2%) 4 (5.8%) 3 (7.5%) 3 (6.3%)
CXR + CT-chest (%) 18 (20.5%) 22 (31.9%) 18 (45.0%) 20 (41.7%)
Abdominal imaging:
Reported in (%) 38 (43.2%) 44 (63.8%) 29 (72.5%) 26 (54.2%)
Total imaging tests of abdomen (% of total of 213) 61 (28.6%) 60 (28.2%) 51 (23.9%) 41 (19.2%)
Imaging details:
US only (%) 23 (26.1%) 28 (40.6%) 11 (27.5%) 12 (25.0%)
CT only (%) 1 (1.1%) 7 (10.1%) 4 (10%) 4 (8.3%)
MRI only (%) 1 (1.1%) 1 (1.4%) 1 (2.5%) 0 (0%)
Two or more of US/CT/MRI (%) 13 (14.8%) 8 (11.6%) 13 (32.5%) 10 (20.8%)
Skeletal imaging: (all reported isotope bone scan)
Reported in (%) 45 (51.1%) 49 (71.0%) 35 (87.5%) 31 (64.6%)
Legend: CXR: chest x-ray; CT: computerized tomography; MRI: magnetic resonance imaging; US: ultrasonography; %: percentage.
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costs) and to the health care system (e.g. costs of im-
aging, delayed access to care) (Gerber et al. 2003;
Schnipper et al. 2012; Morris et al. 2009). The rates of
breast cancer imaging, especially the use of more ad-
vanced imaging modalities are on the rise as are their as-
sociated costs (Mariotto et al. 2011; Dinan et al. 2010;
Crivello et al. 2013; Gold et al. 2013). This specific issue
was recently highlighted by the American Society of
Clinical Oncology (ASCO) in their recent “Top-5” list
for “Choosing Wisely” in oncology (Schnipper et al.
2012). While strategies to promote adherence with
guidelines include widespread guideline dissemination
(Davis and Taylor-Vaisey 1997), physician interventions
(McWhirter et al. 2007), there is little evidence that
these strategies result in sustained practice changes(Graham et al. 2013; Grimshaw et al. 2012). Interest-
ingly, relatively little is known about what patients be-
lieve is important when it comes to radiologic staging
and to our knowledge this is the first study to report
what patient expectations and beliefs are with respect to
staging imaging for distant metastatic disease.
In this study, patients recalled having a significant
amount of imaging performed. Overall, 80.2% of all re-
spondents indicated having at least one imaging test for
an average of 3.5 imaging tests per patient imaged with
the majority of all imaging done in the pre-operative set-
ting (67.9%). Although these data are based completely
on recall, and not verified with the patient record, they
are in keeping with the findings of a recent retrospective
review at the same centre (Simos et al. 2013). In that
study 167 of the 200 patients reviewed (83.5%) had at
Figure 1 Patient reported imaging thresholds (N = 245).
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the number of imaging tests per patient imaged was 3.8
with 61.0% being performed pre-operatively (Simos et al.
2013). The similarity of findings between these two stud-
ies suggest that although the imaging reported in this
study is all based on recall, it is also a reasonably accur-
ate representation of what was actually done and con-
sistent with the over-imaging that is reported in the
literature (McWhirter et al. 2007; Puglisi et al. 2005;
Gerber et al. 2003; Dillman and Chico 2000; Samant and
Ganguly 1999; Ravaioli et al. 1998; Al-Husaini et al. 2008).
These findings are in excess of the recommendations ofFigure 2 Patient reported factors of importance (N = 245), QOL: qualiour provincial guideline (Cancer Care Ontario) which rec-
ommends stage 2 patients should only have a bone scan
and that only stage 3 patients should have imaging of the
thorax, abdomen and skeleton (Myers et al. 2001).
The timing of imaging reported in this study (and also
our previous review (Simos et al. 2013)) suggests most
of the staging imaging to look for distant metastases is
done in the pre-operative period. This is an interesting
finding given that our provincial guideline recommends
staging imaging based on post-operative pathologic stage
(Myers et al. 2001). The reasons why almost twice as
many patients are having radiologic staging done beforety of life.
Figure 3 Patient reported level of comfort if imaging not ordered (N = 245).
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but personal communication with our local surgical col-
leagues revealed reasons as; 1) a significant proportion
of patients already had their staging tests ordered by
their primary care physician 2) the surgeon’s desire to
potentially reduce the wait time for medical and radi-
ation oncology consultations after surgery 3) the poten-
tial to identify metastatic patients early to avoid surgery
as primary therapy, and 4) requests from patients. Clearly,
strategies to promote knowledge translation and adher-
ence to practice guidelines need to target health care pro-
viders at all levels, including the primary care physician,
surgeon, and oncologists.
Participants were asked about what the threshold for
having distant metastases should be to justify the use of
imaging. The majority of patients believed that imaging
should be performed if the chance of detecting distant
metastases was between 6-10%. In other words, most pa-
tients believe that a likelihood of detecting metastatic
disease of >5% and this is an interesting finding in the
context of reported likelihoods of detecting metastatic
disease. Recently, a large meta-analysis reported that the
median prevalence of detecting radiologically evident
metastases in asymptomatic patients with stage 1, 2
and 3 disease were 0.2%, 1.2%, and 8.0%, respectively
(Brennan and Houssami 2012). As the likelihoods of
detecting occult metastases using imaging in stage 1
and 2 disease by are less than the 5% threshold reported by
the patients completing this study, it can be reasoned that
most patients who took part in our study do not believe
imaging is indicated for stage 1 or 2 disease. Interestingly,
our provincial guideline (Cancer Care Ontario guideline)
sets a 1% prevalence cut-off value as the threshold for
consideration of imaging (Myers et al. 2001).
The majority of respondents indicated that “catching
the spread of cancer to other parts of the body early”,
“reducing the chances of dying from breast cancer”, and“providing peace of mind” were very important or ex-
tremely important to them. However, this is quite differ-
ent from the primary reason why most physicians order
imaging, which is for detecting overt metastases in the
asymptomatic setting. In reality, detection of metastatic
disease neither “catches the spread of cancer to other
parts of the body early” nor “reduces the chances of
dying from breast cancer”. However, if imaging is being
performed to “rule out in the presence of metastatic
disease” it is clearly evident that many patients will re-
lapse despite the presence of “normal” imaging. Further
highlighting this discrepancy between physician and pa-
tient perceptions and expectations is that the overwhelm-
ing majority of patients indicated that they would feel
uncomfortable if their physician did not order imaging to
look for metastatic disease in their circumstance, even if
this physician choice was in keeping with the evidence
based guidelines. Only 13.9% indicated that they would
feel very comfortable with this recommendation, and this
is despite 80.0% of respondents indicating that they would
do whatever their doctor recommends.
There are limitations to this study. Given that this was
a questionnaire based study at a single cancer centre,
there is always the issue of recall bias, social response
bias, leading to incomplete or erroneous data. As we de-
liberately did not capture patient identification data, we
were unable to verify the concordance between patient
recall and their medical record. However, the rate and
timing of imaging reported by patients in this study are
very similar those reported in our prior retrospective re-
view (Simos et al. 2013). Furthermore, we have not in-
cluded confounding variables such as the use of breast
imaging as this is used for locoregional detection of cancer
spread and not for the detection of distant metastases.
In conclusion, we have demonstrated that patients
with early stage primary operable breast cancer recall
having undergone a significant amount of imaging. More
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perceptions and expectations are generally not in keeping
with guideline recommendations not to image. The rea-
sons behind this disconnect are unclear but clearly we
need to improve the way patients are informed about the
potential benefits and harms of imaging. Further work is
needed on how to successfully change such practice in
light of the recently published American Society of Clin-
ical Oncology (ASCO) “Top-5” list in Oncology which
identified excessive imaging in early stage breast cancer as
an unnecessary and potentially harmful practice.
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